As announced last week, four significant Canada focused public cannabis companies are to report earnings and issue other reports, especially post-legalization commentaries --- Aurora Cannabis Inc., Tilray Inc., Cronos Group Inc., and Canopy Growth Corp. Today’ public company review is Canopy Growth Corp.
Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, soft gel capsules, and hemp. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Canopy Growth Corporation (CGC) 38.48
Earnings report: Canopy Growth reports Q2 (Sep) results, misses on revs. Reports Q2 (Sep) loss of CAD $1.52 per share, may not be comparable to the single analyst estimate of (CAD $0.10); revenues rose 32.4% year/year to CAD $23.3 mln vs the CC$59.1 mln S&P Capital IQ Consensus.
Overview: During the second quarter of fiscal 2019 ended September 30, 2018, the Company sold 2,197 kilograms and kilogram equivalents at an average sale price of $9.87, up from 2,020 kilograms and kilogram equivalents at an average price of $7.99 in the prior year period, representing an increase of 9% and 24% respectively. Adjusted EBITDA in the second quarter fiscal 2019 amounted to a loss of $57.7 million compared to a loss of $4.8 million in the same period last year. Other expenses of $115.7 million are primarily made up of fair value changes on financial assets and financial liabilities, the majority of which is non-cash. The $115.7 million in other expenses described above, accounted for $0.52 of the reported $1.52 loss per basic and diluted share in the quarter, compared to net loss of $0.01 per basic and diluted share in the comparative period last year.
Commentary: The growing, possession, and sale of medical cannabis is not a long-term business model to warrant further investment commitment. If you purchased CGC in the $20 range (near the 52 week low) as suggested, the current value should be a good reason to a SELL. With a market capitalization of $11.59 billion (that’s right BILLION), and leveraged Free Cash Flow $ -234.94 million, CGC is overpriced and overextended. It is a business model that will not work in the current environment.
Valuation Measures
Market Cap (intraday) 11.59B
Enterprise Value 7.93B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) 1 N/A
Price/Sales (ttm) 175.21
Price/Book (mrq) 8.08
Enterprise Value/Revenue 119.83
Enterprise Value/EBITDA -126.65
Financial Highlights
Currency in CAD.
Fiscal Year
Fiscal Year Ends Mar 30, 2018
Most Recent Quarter (mrq) Jun 29, 2018
Profitability
Profit Margin -160.90%
Operating Margin (ttm) -118.53%
Management Effectiveness
Return on Assets (ttm) -4.57%
Return on Equity (ttm) -14.25%
Income Statement
Revenue (ttm) 66.14M
Revenue Per Share (ttm) 0.35
Quarterly Revenue Growth (yoy) 63.30%
Gross Profit (ttm) 74.19M
EBITDA -62.58M
Net Income Avi to Common (ttm) -106.43M
Diluted EPS (ttm) -0.5710
Quarterly Earnings Growth (yoy) N/A
Balance Sheet
Total Cash (mrq) 494.55M
Total Cash Per Share (mrq) 2.45
Total Debt (mrq) 466.28M
Total Debt/Equity (mrq) 50.66
Current Ratio (mrq) 6.84
Book Value Per Share (mrq) 4.24
Cash Flow Statement
Operating Cash Flow (ttm) -102.8M
Levered Free Cash Flow (ttm) -234.94M
Trading Information
Stock Price History
Beta (3Y Monthly) 2.43
52-Week Change ∞%
S&P500 52-Week Change 5.56%
52 Week High 59.25
52 Week Low 16.74
50-Day Moving Average 44.65
200-Day Moving Average 35.81
Share Statistics
Avg Vol (3 month) 15.49M
Avg Vol (10 day) 13.67M
Shares Outstanding 201.55M
Float 123.77M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short (Oct 30, 2018) 16.06M
Short Ratio (Oct 30, 2018) 1.19
Short % of Float (Oct 30, 2018) N/A
Short % of Shares Outstanding (Oct 30, 2018) 7.21%
Shares Short (prior month Sep 27, 2018) 13.83M